Play Earnings CallPlay Earnings Call
Axsome Therapeutics, Inc. (AXSM) Leerink Global Healthcare Conference 2026 March 9, 2026 4:20 PM EDT
Company Participants
Nick Pizzie – Chief Financial Officer
Mark Jacobson – Chief Operating Officer
Conference Call Participants
Marc Goodman – Leerink Partners LLC, Research Division
Presentation
Marc Goodman
Leerink Partners LLC, Research Division
Thanks, everybody, for joining. Sorry we’re a little late. logistical issues, but we’re good. I’m Marc Goodman, one of the biopharma analysts at Leerink, and we’re lucky enough to have Axsome Therapeutics with us. And we have Mark Jacobson, who’s the COO; and Nick Pizzie, who’s the CFO. Thanks, guys, for joining us.
Question-and-Answer Session
Marc Goodman
Leerink Partners LLC, Research Division
So why don’t we just start with Auvelity and just give us kind of a little bit of a load down on what’s happening with Auvelity right now, just from a marketing strategy perspective, how you’re thinking about things this year relative to what you were doing last year and the year before? What’s changing?
Nick Pizzie
Chief Financial Officer
Sure. Yes. Maybe I’ll start. Thanks for having us, Marc. So Auvelity ended the year last year, annualizing just north of $600 million, and it is the third full year since launch in 2022. So really pleased with the performance. We’re outpacing some of the peers in the space. So very pleased with that. And that was with, I’ll say, a smaller field force. We started with 160, did an expansion in ’24 to 260 and then got to the most recent levels of 300 in 2025. And also with market access, that has evolved and improved over time. And currently, we’re at 86% coverage.
So been pleased with the performance from a revenue perspective and script growth. One of the things that we are doing in 2026 is expanding the
